Technology that “sees inside” the brain has enabled researchers to conclude that people with schizophrenia have less brain tissue at their first episode of illness than healthy individuals — and that antipsychotic medication is tied to further tissue loss.
In a new study, University of Iowa psychiatry professor Nancy Andreasen, Ph.D., discussed how MRI scans have documented brain changes from 200 patients beginning with their first episode and continuing with scans at regular intervals for up to 15 years.
The study in the American Journal of Psychiatry is considered the largest longitudinal, brain-scan data set ever compiled, Andreasen said.
“There are several studies, mine included, that show people with schizophrenia have smaller-than-average cranial size,” she said.
“Since cranial development is completed within the first few years of life, there may be some aspect of earliest development—perhaps things such as pregnancy complications or exposure to viruses—that on average, affected people with schizophrenia.”
Schizophrenia affects roughly 3.5 million people, or about one percent of the U.S. population, according to the National Institutes of Health. Globally, some 24 million are affected, according to the World Health Organization.
Andreasen and her lab are also using brain scans from magnetic resonance imaging to better understand how anti-psychotic drugs affect the brains of schizophrenia patients.
Andreasen’s team learned from the brain scans that those affected with schizophrenia suffered the most brain tissue loss in the two years after the first episode, but then the damage curiously stabilizes—to the group’s surprise.
The finding may help doctors identify the most effective time periods to prevent tissue loss and other negative effects of the illness, Andreasen said.
The researchers also analyzed the effect of medication on the brain tissue. Although results were not the same for every patient, the group found that in general, the higher the anti-psychotic medication doses, the greater the loss of brain tissue.
“This was a very upsetting finding,” Andreasen said.
“We spent a couple of years analyzing the data more or less hoping we had made a mistake. But in the end, it was a solid finding that wasn’t going to go away, so we decided to go ahead and publish it.
“The impact is painful because psychiatrists, patients and family members don’t know how to interpret this finding. ‘Should we stop using antipsychotic medication? Should we be using less?’”
The group also examined how relapses could affect brain tissue, including whether long periods of psychosis could be toxic to the brain. The results suggest that longer relapses were associated with brain tissue loss.
The insight could change how physicians use antipsychotic drugs to treat schizophrenia, with the view that those with the disorder can lead productive lives with the right balance of care.
“We used to have hundreds of thousands of people chronically hospitalized. Now, most are living in the community, and this is thanks to the medications we have,” Andreasen said.
“But antipsychotic treatment has a negative impact on the brain, so … we must get the word out that they should be used with great care, because even though they have fewer side effects than some of the other medications we use, they are certainly not trouble free and can have lifelong consequences for the health and happiness of the people and families we serve.”
Source: University of Iowa